WO2008099913A1 - ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 - Google Patents

ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 Download PDF

Info

Publication number
WO2008099913A1
WO2008099913A1 PCT/JP2008/052500 JP2008052500W WO2008099913A1 WO 2008099913 A1 WO2008099913 A1 WO 2008099913A1 JP 2008052500 W JP2008052500 W JP 2008052500W WO 2008099913 A1 WO2008099913 A1 WO 2008099913A1
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb
antibody
active ingredient
therapeutic agent
antibody capable
Prior art date
Application number
PCT/JP2008/052500
Other languages
English (en)
French (fr)
Inventor
Yukio Ando
Ikuro Maruyama
Shingo Yamada
Original Assignee
Kumamoto University
Kagoshima University
Shino-Test Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kumamoto University, Kagoshima University, Shino-Test Corporation filed Critical Kumamoto University
Priority to JP2008558144A priority Critical patent/JP5225109B2/ja
Priority to US12/449,543 priority patent/US8470325B2/en
Priority to EP08711330A priority patent/EP2123297A4/en
Publication of WO2008099913A1 publication Critical patent/WO2008099913A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　従来、HMGB-2に結合することなくHMGB-1に特異的に結合し、かつ親和性の高い抗体を得ることは容易ではなかった。このような中、本発明者らは、特定のペプチドを抗原として用いることによって、HMGB-2よりもHMGB-1に強く反応する抗体を取得することに成功した。また本発明者らは、上記抗体がHMGB-1に対して中和活性を有することを見出した。本発明者らは、上記抗体をアミロイドシスの疾患モデル動物に投与した結果、顕著な治療効果が得られることを実証することに成功した。
PCT/JP2008/052500 2007-02-15 2008-02-15 ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 WO2008099913A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008558144A JP5225109B2 (ja) 2007-02-15 2008-02-15 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
US12/449,543 US8470325B2 (en) 2007-02-15 2008-02-15 Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
EP08711330A EP2123297A4 (en) 2007-02-15 2008-02-15 THERAPEUTIC AGENT COMPRISING AN ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HMGB-1 AS ACTIVE INGREDIENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034325 2007-02-15
JP2007-034325 2007-02-15

Publications (1)

Publication Number Publication Date
WO2008099913A1 true WO2008099913A1 (ja) 2008-08-21

Family

ID=39690138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052500 WO2008099913A1 (ja) 2007-02-15 2008-02-15 ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤

Country Status (5)

Country Link
US (1) US8470325B2 (ja)
EP (1) EP2123297A4 (ja)
JP (1) JP5225109B2 (ja)
TW (1) TW200902063A (ja)
WO (1) WO2008099913A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059847A1 (ja) 2018-09-21 2020-03-26 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
US10730937B2 (en) 2016-08-09 2020-08-04 National University Corporation Tokyo Medical And Dental University Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody
TW200900077A (en) * 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534351A (ja) * 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP2004107260A (ja) * 2002-09-18 2004-04-08 Takeda Chem Ind Ltd 脳アミロイドーシス予防・治療薬のスクリーニング方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (en) 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
CA2262443A1 (en) * 1996-07-17 1998-01-22 Kaneka Corporation Diagnostic drugs for autoimmune diseases
JP3267893B2 (ja) 1997-05-15 2002-03-25 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
CA2447576C (en) * 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4823465B2 (ja) 2001-07-13 2011-11-24 株式会社シノテスト ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
DE50212280D1 (de) 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE60326453D1 (de) 2002-07-03 2009-04-16 Ct Cardiologico Monzino S P A Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
JP2006506441A (ja) 2002-11-20 2006-02-23 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
CA2585043A1 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
US20100040607A1 (en) 2005-05-13 2010-02-18 Tracey Kevin J Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
EP2380983A3 (en) * 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE fusion proteins, formulations, and methods of use thereof
TW200900077A (en) * 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534351A (ja) * 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP2004107260A (ja) * 2002-09-18 2004-04-08 Takeda Chem Ind Ltd 脳アミロイドーシス予防・治療薬のスクリーニング方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2123297A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730937B2 (en) 2016-08-09 2020-08-04 National University Corporation Tokyo Medical And Dental University Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease
WO2020059847A1 (ja) 2018-09-21 2020-03-26 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物

Also Published As

Publication number Publication date
TW200902063A (en) 2009-01-16
US8470325B2 (en) 2013-06-25
EP2123297A1 (en) 2009-11-25
EP2123297A4 (en) 2011-10-12
JP5225109B2 (ja) 2013-07-03
JPWO2008099913A1 (ja) 2010-05-27
US20110229487A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
NZ598524A (en) Therapeutic dll4 binding proteins
WO2008099913A1 (ja) ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
NZ602166A (en) Antibodies to il-6 and use thereof
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
EP4303237A3 (en) Cytotoxicity-inducing therapeutic agent
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
WO2006033700A3 (en) Her2 antibody composition
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
JOP20110402B1 (ar) الأجسام المضادة ل cd38
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2009051220A1 (ja) Aβオリゴマーに特異的に結合する抗体およびその利用
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
WO2011107653A3 (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2009054471A1 (ja) 免疫誘導剤
WO2013061083A3 (en) Therapeutic agents and uses thereof
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711330

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008558144

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008711330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449543

Country of ref document: US